Webinar Date/Time: Wednesday, May 15th, 2024 at 10am EDT | 7am PDT | 3pm BST | 4pm CEST
Are you using the most appropriate data to understand the patient journey and improve your oncology clinical trial design? Register to learn how real-world data can provide more precise estimations of specific oncology patient sub-populations to yield shorter recruitment times and avoid costly amendments.
Register Free: https://globalmeet.webcasts.com/starthere.jsp?ei=1663847&tp_key=a90a159aa5
Event Overview:
Traditional data sources can be incomplete and do not always adequately account for regional differences in prevalence of oncology sub-populations. This can lead to inaccurate estimations being used for clinical trial design, resulting in patient recruitment challenges and increased risk of costly amendments.
This webinar illustrates how real-world data (RWD) yields patient journey insights and more precise estimations of specific oncology patient sub-populations that can be used to optimize oncology clinical trial design and reap significant benefits.
Three Key Take-Aways:
Speakers:
Sergio Sánchez-Gambetta, MD
Design Analytics Director
IQVIA
Sergio Sánchez-Gambetta, based in Perú, South America, joined IQVIA in January 2023. In his role, he collaborates with other clinical trial experts to deliver analytic-based protocol assessment insights, helping sponsors make informed trial design strategy decisions.
Sergio is a MD and holds a master’s degree in Epidemiology (quantitative methods focus). He has >17 years’ experience across clinical research, real world data/evidence applications, study start up and medical affairs. He has held various roles at research centers, global CROs and Roche Pharmaceuticals.
Sergio has been teaching within the Clinical Research master’s and diploma programs at 3 Peruvian Universities since 2017. In 2020, he became an external member of a Local Ethics Committee, where he reviews Medical Device protocols and projects. Along with his peers, he participates in analysing data and contributing to medical publications.
Register Free: https://globalmeet.webcasts.com/starthere.jsp?ei=1663847&tp_key=a90a159aa5
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
ROI and Rare Disease: Retooling the ‘Gene’ Value Machine
November 14th 2024Framework proposes three strategies designed to address the unique challenges of personalized and genetic therapies for rare diseases—and increase the probability of economic success for a new wave of potential curative treatments for these conditions.
Cell and Gene Therapy Check-in 2024
January 18th 2024Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.